【巴黎讯】法国AI生物科学初创公司Bioptimus近日宣布，其在成立数月后已成功完成3500万美元的种子轮融资，此举彰显了投资者对该公司创新理念的强烈信心。Bioptimus致力于利用人工智能技术为生物技术领域构建大规模语言模型，以期推动生物科技的革新与发展。
本轮融资由法国知名生命科学风险投资公司Sofinnova Partners和公共银行Bpifrance Large Ventures共同领投，显示了业界对Bioptimus前景的积极预期。此外，法国风险投资公司Frst、全球投资机构Cathay Innovation，以及来自美国的投资者Headline和Owkin，以及亿万富翁企业家Xavier Niel也纷纷加入投资阵容，为Bioptimus的发展注入了强大的资本支持。
Bioptimus的这一轮融资不仅为公司提供了充足的研发资金，也将助力其加速构建生物技术领域的AI语言模型，以解决行业内的复杂问题并提升研究效率。公司的这一创新举措有望为全球生物科技产业带来颠覆性的变化，进一步推动生命科学与人工智能的深度融合。
Bioptimus的快速崛起和资本市场的热烈响应，凸显了AI在生物科学领域的巨大潜力和投资价值。随着科技的不断进步，预计未来将有更多的初创公司利用AI技术重塑生物科技的未来。
英语如下：
**News Title:** “Bioptimus Raises $35 Million Seed Funding to Develop AI Language Models for Bioscience”
**Keywords:** Bioptimus, Seed Round, $35 Million
**News Content:**
**Paris, France** – French AI-driven bioscience startup Bioptimus has recently announced that it has successfully closed a $35 million seed funding round just months after its inception, demonstrating strong investor confidence in the company’s innovative vision. Bioptimus is dedicated to leveraging artificial intelligence to build large-scale language models for the biotechnology sector, aiming to revolutionize and advance the field of biotech.
The current funding round was led by prominent life sciences venture capital firm Sofinnova Partners and public bank Bpifrance Large Ventures, indicating a positive outlook for Bioptimus’s future. Additionally, French venture capital firm Frst, global investment firm Cathay Innovation, and American investors Headline and Owkin, as well as billionaire entrepreneur Xavier Niel, have also joined the investor lineup, injecting substantial capital support into Bioptimus’s growth.
This fundraising not only provides ample resources for the company’s research and development but also accelerates its efforts to build AI language models in biotechnology, addressing complex industry issues and boosting research efficiency. Bioptimus’s innovative approach is poised to bring transformative changes to the global biotech industry, fostering a deeper integration of life sciences with artificial intelligence.
The rapid ascent of Bioptimus and the enthusiastic response from the capital market highlight the immense potential and investment value of AI in the bioscience sector. With ongoing technological advancements, it is anticipated that more startups will leverage AI technology to reshape the future of biotechnology.
【来源】https://sifted.eu/articles/bioptimus-owkin-35m-seed
Views: 1